Work

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

Year: 2023

Type: article

Study design: Clinical Trial

Source: Clinical Lung Cancer

DOI: 10.1016/j.cllc.2023.01.013

Authors: Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard Chao, Balazs Halmos

Institutions: Sarah Cannon, Mary Crowley Cancer Research Center, Masonic Cancer Center, University of California, Los Angeles, University of Washington, Fred Hutch Cancer Center, Mirati Therapeutics (United States), Montefiore Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: AstraZeneca, Merck, Mirati Therapeutics

OpenAlex ID: W4319335333

FWCI: 2.578

Cites: 46

Cited by: 25

Related to: 10